Diazyme Presents Clinical Chemistry Assays for Cancer Biomarkers and Diabetes at MEDICA 2026

By LabMedica International staff writers
Posted on 19 Nov 2026

Diazyme Laboratories (Poway, CA, USA) is showcasing its clinical chemistry assay portfolio at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. Its exhibit at Hall 3, Stand D15-1 covers gastrointestinal health markers, free light chains, total bile acids, and vitamin D testing. The display also features the Human Kappa Free Light Chain Assay, α-Fetoprotein (AFP) Assay, and Direct HbA1c (Enzymatic, On-Board Lysis) Assay, highlighting applications in cancer-related biomarker testing and diabetes monitoring.

Among the featured products, Diazyme’s Human Kappa Free Light Chain Assay uses latex-enhanced immunoturbidimetry to quantify kappa free light chains in serum. Combined with lambda free light chain measurements and other clinical findings, these results aid in diagnosing and monitoring multiple myeloma. Precision testing conducted according to CLSI EP5-A guidelines demonstrated within-run precision of 1.1%–7.9% and total precision of 1.7%–11.7%.


Image: At Hall 3, Stand D15-1, DIazyme is highlighting diagnostic solutions covering gastrointestinal health markers, free light chains, total bile acids, and vitamin D testing (Photo courtesy of Diazyme)

For cancer-related biomarker testing, Diazyme is also presenting its α-Fetoprotein (AFP) Assay, a dual liquid-stable reagent system that measures AFP to support evaluation of certain cancers, including hepatocellular carcinoma. Requiring 7 µL of serum or plasma, the assay delivers results in less than 10 minutes. Comparisons with commercial assays demonstrated an R² value of 0.9793 and a slope of 0.999, while within-run precision was below 7.6%. 

Another featured product is the Direct HbA1c (Enzymatic, On-Board Lysis) Assay, designed for high-throughput glycated hemoglobin testing without offline sample pretreatment. The assay uses a patented single-channel enzymatic method that eliminates the need for a separate total hemoglobin measurement channel, helping improve laboratory turnaround time. It provides an analytical measurement range of 4.0%–12.0% HbA1c and is designed to minimize interference from hemoglobin variants and post-translational modifications. 


Latest Medica 2026 News